Maravai LifeSciences Holdings, Inc. (MRVI)

7.70 +0.12 (+1.58%) At close: 04:00PM EDT

Maravai LifeSciences Holdings, Inc.

10770 Wateridge Circle
Suite 200
San Diego, CA 92121
United States
858 546 0004
https://www.maravai.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 650

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Carl W. Hull	Co-Founder & Executive Chairman	617.67k	N/A	1959
Mr. William E. Martin III	Chief Executive Officer	987.86k	N/A	1975
Mr. Kevin M. Herde	Executive VP & CFO	548.62k	N/A	1972
Dr. Peter Michael Leddy Ph.D.	Executive VP & Chief Administrative Officer	583.39k	N/A	1963
Ms. Christine Dolan	Executive VP & GM of Cygnus Technologies	536.63k	N/A	1968
Mr. Andrew Burch	President of Nucleic Acid Production	425.15k	N/A	1969
Ms. Debra Hart	Senior Director of Investor Relations	N/A	N/A	N/A
Mr. Kurt Oreshack	Executive VP, General Counsel & Secretary	701.4k	N/A	1981
Ms. Rebecca Buzzeo	Executive VP & Chief Commercial Officer	N/A	N/A	N/A
Dr. Kate E. Broderick Ph.D.	Chief Innovation Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Corporate governance

Maravai LifeSciences Holdings, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 2; Board: 10; Shareholder rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.